Analyst Price Targets — CMPS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 27, 2026 9:24 am | Benjamin Burnett | Wells Fargo | $13.00 | $11.26 | TheFly | Compass Pathways initiated with an Equal Weight at Wells Fargo |
| July 20, 2026 11:10 am | Madison El-Saadi | B.Riley Financial | $17.00 | $12.35 | StreetInsider | B.Riley Reiterates Buy Rating on Compass Pathways (CMPS) |
| July 7, 2026 8:33 pm | Paul Matteis | Stifel Nicolaus | $21.00 | $12.99 | StreetInsider | Compass Pathways (CMPS) PT Raised to $21 at Stifel |
| July 7, 2026 4:10 pm | — | Compass Point | $25.00 | $13.12 | StreetInsider | Compass Pathways (CMPS) PT Raised to $25 at BTIG, 'executed nearly flawlessly on everything within its control'Member Login |
| May 15, 2026 12:45 pm | Jason McCarthy | Maxim Group | $20.00 | $10.40 | TheFly | Compass Pathways price target raised to $20 from $12 at Maxim |
| May 14, 2026 12:07 pm | Judah Frommer | Morgan Stanley | $17.00 | $10.94 | TheFly | Compass Pathways price target raised to $17 from $16 at Morgan Stanley |
| May 7, 2026 2:26 pm | — | UBS | $18.00 | $9.26 | TheFly | Psychedelic: Jefferies initiates Compass Pathways with a Buy rating |
| May 3, 2026 11:52 pm | — | Jefferies | $18.00 | $9.01 | TheFly | Compass Pathways initiated with a Buy at Jefferies |
| April 24, 2026 12:50 pm | — | UBS | $17.00 | $8.87 | TheFly | Compass Pathways initiated with a Buy at B. Riley |
| February 18, 2026 1:33 pm | — | RBC Capital | $22.00 | $8.78 | TheFly | Compass Pathways price target raised to $22 from $21 at RBC Capital |
Latest News for CMPS
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the…
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of…
Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Compass Pathways' COMP360 offers a capacity advantage over Spravato, enabling four times more patients per monitored hour and supporting higher peak sales estimates. Regulatory momentum is strong, but timing risk exists due to DEA rescheduling, which could create interim share price volatility.
COMPASS Pathways remains a Buy, but Eli Lilly's acquisition of AtaiBeckley narrows CMPS's long-term strategic options. COMP360's first-mover advantage in treatment-resistant depression is real but fragile, with approval targeted for H1 2027 and launch timelines described as fluid. BPL-003's short-duration sessions may offer superior site economics versus CMPS's 6-hour COMP360 protocol, raising competitive risks.
Compass Pathways NASDAQ: CMPS said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CMPS.
U.S. House Trading
No House trades found for CMPS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.